Drug class

The Small-molecule GLP-1 class

Small-molecule GLP-1 medications, with sourced prices, shortage reports and study results.

Last updated

Last checked · Nov 16, 2026 UTC
1approved
1in development

Approved in this class

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

Orforglipron

Foundayo

FDA-approved for

  • Weight loss

Oral tablet (any time of day, no food or water restriction) · Once daily

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT)

Foundayo via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Word for word

How Small-molecule GLP-1 medicines work

From the Mechanism of Action section of each manufacturer's current FDA label.

  • Foundayo: “FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite.”FDA label, revised Jul 29, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine to
Foundayo17.2 mg from day 151about 29 to 49 hoursNoSep 26, 2037

How long each takes · Generics and patents · Who covers what

Investigational (pipeline)

Alphabetical by active ingredient. These entries are not FDA-approved for this category; open a record for the studied uses and evidence.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.